GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Other Operating Expense

Diamyd Medical AB (OSTO:DMYD B) Other Operating Expense : kr55.91 Mil (TTM As of May. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Other Operating Expense?

Diamyd Medical AB's Other Operating Expense for the three months ended in May. 2025 was kr15.49 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in May. 2025 was kr55.91 Mil.

Diamyd Medical AB's quarterly Other Operating Expense declined from Nov. 2024 (kr15.77 Mil) to Feb. 2025 (kr13.43 Mil) but then increased from Feb. 2025 (kr13.43 Mil) to May. 2025 (kr15.49 Mil).

Diamyd Medical AB's annual Other Operating Expense increased from Aug. 2022 (kr35.42 Mil) to Aug. 2023 (kr42.85 Mil) and increased from Aug. 2023 (kr42.85 Mil) to Aug. 2024 (kr47.21 Mil).


Diamyd Medical AB Other Operating Expense Historical Data

The historical data trend for Diamyd Medical AB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Other Operating Expense Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.70 26.77 35.42 42.85 47.21

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.86 11.22 15.77 13.43 15.49

Diamyd Medical AB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in May. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr55.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines